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Background and Objectives
 
Although parvovirus B19 is a significant blood product
contaminant, few methods other than polymerase chain reaction (PCR) have been
developed to detect the presence of the virus.
 
Material and Methods
 
A B19 antigen enzyme immunoassay (EIA) has been developed
and the sensitivity of detection is ascertained using dilutions of the B19 capsid
protein VP2 and 10-fold dilutions of B19 viraemic serum. Once the assay cut-off was
established, a panel of viraemic donations (
 
n
 
 = 70) was screened by the antigen EIA.
The B19 immunoglobulin M (IgM) and IgG status of these specimens was also
determined. During screening of blood donor units by quantitative PCR, 70 individuals
were identified with levels of B19 DNA greater than 10
 
6
 
 IU/ml at the time of blood
donation.
 
Results
 
The sensitivity of the B19 antigen EIA was estimated to be equivalent to
between 10
 
8
 
 and 10
 
9
 
 IU/ml B19 DNA or 1–10 pg/ml of recombinant capsid protein.
B19 detection was significantly enhanced when viraemic specimens were pretreated
with a low pH proprietary reagent. Unlike other virus-detection assays, detection of
the B19 antigen was not affected by the presence of B19 IgM or IgG antibodies. In
addition, the assay was capable of detecting all three genotypes of human erythrovirus.
Combined specimen analysis by the B19 antigen assay and a B19 IgM assay facilitated
the detection of 91% of acute B19 infections in the test population.
 
Conclusion
 
In combination with B19 IgM detection, application of the B19 antigen
EIA is a flexible and efficient method of detecting recent B19 infection and can
be used as an alternative to PCR.
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Introduction
 
Parvovirus B19 (B19V) infection of immunocompromised
patients may result in severe morbidity and mortality [1,2].
Moreover, B19 infection of pregnant women may lead to
fetal death [3]. The recent implementation of minipool
polymerase chain reaction (PCR) screening procedures for
pooled plasma, combined with mandatory European guidelines
on acceptable B19 contamination of human immunoglobulin
preparations (< 10 000 IU/ml B19 DNA), will minimize
B19 contamination and improve the safety of pooled blood
products [4,5]. However, the extremely high levels of B19
viraemia in recently infected individuals (10
 
13
 
 IU B19 DNA/ml)
[6], asymptomatic B19 infections and the resilience of the
virus to many of the virus-inactivation procedures mean that
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B19 screening and elimination are still problematic [7,8].
Although PCR is currently the method of choice, contamination
issues during screening [9], accurate erythrovirus genotype
detection [10] and lack of individual donation screening
necessitate continual evaluation of emerging technologies to
ensure blood product safety.
Currently, B19 viral capsid protein production 
 
in vivo
 
 is
detected by immunofluorescent staining and receptor-
mediated haemagglutination (RHA) assays whereas viral
DNA production is detected by PCR, dot blot hybridization
and quantitative PCR (qPCR) [11–15]. RHA does not detect
the B19 antigen at the required sensitivity in specimens that
contain B19 IgG/M [11,15]. This is unacceptable especially
when B19 IgG positive solvent/detergent-treated plasma,
contaminated with B19 DNA, has been shown to transmit
infection [16].
B19 antigen detection by enzyme immunoassay (EIA) is
an alternative strategy for individual donor screening but
may also be confounded by low assay sensitivity, differential
reactivity between VP2 capsid and native B19 antigen detection
and B19 antibody presence [17,18]. The B19 antigen assay
described by Lowin 
 
et al
 
. [18] has an apparent sensitivity of
detection for recombinant VP2 capsids of 10
 
8
 
 particles per
ml; however, application of the assay to native B19 antigen
detection was not demonstrated.
Using a Food and Drug Administration (FDA)-cleared B19
IgM EIA [19], Beersma 
 
et al
 
. [20] have shown that in sera with
B19 DNA levels greater than 10
 
6
 
 per ml, B19 IgM reactivity
always exceeds 3·0 (EIA cut-off = 1·0). Thus, it is clear that
the presence of B19 VP2 IgM antibodies in sera is predictive
for the presence of B19 DNA. This observation represents the
first data unambiguously correlating B19 viral load with IgM
antibody levels. Importantly, it also provides for an alternative
strategy, employing simultaneous B19 IgM and antigen
detection, to overcome the sensitivity issues pertaining to
B19 antigen detection in individual donor units. Here, we
show that such a strategy facilitates detection of B19 antigen
levels in plasma donations.
 
Materials and methods
 
B19 antigen EIA optimization
 
Recombinant B19 VP2 capsids were expressed and purified
as previously described [21] and were used for sheep and rab-
bit immunization. Affinity purified sheep IgG (anti-B19 VP2)
was coated onto microtitre plates (Nunc Maxisorp, Roskilde,
Denmark) and the rabbit IgG (anti-B19 VP2) was conjugated
to horseradish peroxidase (HRP), as described by Hermanson
[22], and was used to detect captured B19 antigen.
Optimal IgG (anti-B19 VP2) plate-coating concentration
(4 
 
µ
 
g/ml) and conjugate dilution (1/4000 dilution) were
established by testing B19-viraemic and non-viraemic plasma
specimens. Dilutions of B19 VP2 capsids from 0·01 to
10 000 ng/ml were also analysed by the antigen EIA to
determine the limit of detection in terms of protein concentra-
tion. The mean absorbance of the negative control for each
batch of VP2 plus three standard deviations was used to set
the assay cut-off value (COV).
To determine sensitivity in terms of B19 viral antigen
detection, viraemic plasma was evaluated (qPCR testing was
performed at the National Genetics Institute, CA, USA and
results were reported in copies/ml). The mean absorbance of
a panel of 201 non-viraemic human plasma samples plus three
standard deviations was used to set the assay COV. This
was matched to a dilution of a B19-viraemic plasma, which
was used in all subsequent assays as a cut-off calibrator and
facilitated determination of the positive or negative status of
specimens tested on the antigen EIA.
 
Specimen preparation and final assay procedure
 
Test plasma and control specimens were diluted (1/5) in a low
pH proprietary diluent (citrate buffer-containing detergents;
available from Biotrin International Ltd., Dublin, Ireland) and
were added to IgG (anti-B19 VP2) sensitized microwells
(100 
 
µ
 
l per well) for 1 h. Following a wash step, the rabbit
IgG (anti-B19 VP2)–HRP conjugate was incubated in the
wells for 30 min. Tetramethylbenzidine substrate (BioFX
Laboratories Inc., Owings Mills, MD, USA) was added to the
wells for 30 min. The reaction was terminated using 1 N
sulphuric acid and the absorbance was measured at 450/630 nm.
The presence of B19 antigen in a sample was determined by
the absorbance ratio of specimen sample to cut-off calibrator
sample (index value; IV). Specimens yielding index values
 
≥
 
 1·0 were classed positive while those < 1·0 were deemed
negative.
 
Parvovirus B19 IgM and IgG
 
All specimens in this study were screened for B19 IgM and
B19 IgG using commercial assays (Biotrin) as described
previously [21].
 
Donor screening by B19 qPCR
 
The blood donor population in The Netherlands was screened
for B19V over an 18-month period (February 2003–July 2004)
using qPCR analysis as described previously [12]. Test
pools of 480 were made from smaller pools of 48 donations.
A pool identified with > 10
 
4
 
 IU/ml B19 DNA was resolved via
test pools of 48 donations and subsequently eight donations
to trace the viraemic donor(s). Identified viraemic donations
(
 
n
 
 = 70) were then used to evaluate the B19 antigen EIA [12].
Results were expressed in IU/ml [23]. The copies-to-IU conversion
factor has been calculated previously to be 3·34 [14].
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Results
 
Assay optimization and validation
 
Figure 1a shows identical standard curves [absorbance 
 
450/630 nm
 
vs. B19 recombinant VP2 capsid concentration (ng/ml)]
generated from two independent batches of recombinant
VP2 capsids in the B19 antigen EIA. These standard curves
show that the minimal detectable level of B19 VP2 capsid
detectable was 0·01 ng/ml, which theoretically equates to
1·9 
 
×
 
 10
 
6
 
 viral particles per ml.
However, detection of B19 viraemic plasma in the same
assay format required the implementation of an alternative
specimen diluent (Fig. 1b). Here, dilution of viraemic specimens
(
 
n
 
 = 16) in a low pH, proprietary diluent, compared to using
Tris-buffered saline Tween-20 (TBST), facilitated a considerable
increase in virus capture in the majority of specimens (0- to
30-fold). Only one specimen (3·9 
 
×
 
 10
 
10
 
 IU/ml B19 DNA) that
was negative for B19 IgM did not display a significant signal
increase post-treatment, but did remain positive. Interestingly,
the two specimens with the highest absorbance values in
the assay without low pH pretreatment were IgM negative.
Non-viraemic plasma remained unreactive when subjected
to the same pretreatment (data not shown). Assay specificity
was determined by screening non-viraemic plasma (
 
n
 
 = 20),
all of which were unreactive in the antigen EIA based on the
cut-off calibrator sample (data not shown).
The assay sensitivity (limit of detection) was estimated
using dilutions of viraemic specimens and was shown to be
approximately between 4 
 
×
 
 10
 
7
 
 and 4 
 
×
 
 10
 
8
 
 copies per ml
B19 DNA (Fig. 2). However, the cut-off calibrator used in the
EIA contained 10
 
9
 
 copies per ml B19 DNA as determined by
qPCR, which equates to 2 
 
×
 
 10
 
7
 
 copies B19 DNA per microwell.
To further define the limit of detection, plasma specimens
(
 
n
 
 = 17), containing a range of B19 DNA concentrations and
B19 IgM/G reactivity, were subsequently screened in the
antigen EIA. Table 1 shows that 53% (9/17) of specimens, all
of which contained greater than 1·4 
 
×
 
 10
 
11
 
 copies per ml B19
DNA, were also detectable in the antigen EIA. One specimen
containing 7·2 
 
×
 
 10
 
8
 
 copies per ml B19 DNA, which was B19
IgM reactive, tested borderline positive (IV = 1·0) in the antigen
EIA. All remaining specimens, which contained less than
1·9 
 
×
 
 10
 
7
 
 copies per ml B19 DNA and either B19 IgM or IgG
or both, were unreactive in the antigen EIA.
Detection of the B19 antigen in the presence of specimen-
derived B19-specific IgG or IgM is essential to avoid false
negativity. Table 2 clearly illustrates that specimen-derived
B19 antigen is detectable in the presence of both B19 IgG and
IgM (
 
n
 
 = 8), IgM only (
 
n
 
 = 2) or IgG only (
 
n
 
 = 3). Furthermore,
B19 antigen is also detectable in specimens Bt72 and Bt73,
which contained B19 IgM (Fig. 2). It is clear, therefore, that
only B19 levels greater than 4 
 
×
 
 10
 
7
 
 B19 DNA copies per ml
are detectable in the antigen EIA and that the presence or
absence of IgM or IgG in the specimen does not affect detection
of the B19 antigen (Fig. 2 and Table 2). A specimen containing
erythrovirus genotype 2 (specimen Bt81) was detected as well
as erythrovirus genotype 1 (specimens Bt72, Bt73 and Bt80)
in the antigen EIA (Fig. 2). Furthermore, erythrovirus genotype
Fig. 1 Determination of B19 antigen enzyme immunoassay (EIA) assay 
sensitivity. (a) Two independent batches of recombinant capsid VP2 (rVP2), 
V056 (circles) and V057 (triangles) were decimally diluted to determine assay 
sensitivity. (b) Comparison of specimen diluents used in the detection of B19 
viral capsids. Specimens were diluted in either Tris-buffered saline Tween-20 
(TBST) (clear boxes) or a low pH proprietary reagent (filled boxes). Error bars 
represent the standard deviation from the mean.
Fig. 2 Determination of antigen assay sensitivity using titrations of 
polymerase chain reaction (PCR)-quantified viraemic specimens. Viraemic 
plasma Bt72 (diamonds), Bt73 (squares), Bt80 (triangles) and genotype 2 
Bt81 (circles) were decimally diluted in B19 negative serum to determine 
assay cut-off.
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3 recombinant VP2 capsids exhibit indistinguishable reactivity
in the assay to genotype 1 recombinant VP2 (Fig. 3).
 
Donor sample evaluation
 
During an 18-month period, approximately 1·4 million
donations were tested for B19 DNA in The Netherlands [14],
and 70 cases of asymptomatic donors (0·005%) with levels of
B19 DNA greater than 10
 
6
 
 IU/ml were identified. Of these,
49/70 (70%) tested positive on the antigen EIA assay for B19
Sample identifier IgM EIA IV IgG EIA IV qPCR (copies per ml) Antigen EIA IV
Cut-off calibrator 6·77 + 0·99 eq 1·3 × 109 1·00 +
W P 0·80 – 0·14 – 6·9 × 1011 18·7 +
C4 0·26 – 0·06 – 6·0 × 1011 > 3·0 +
PL19 0·59 – 0·07 – 5·6 × 1011 > 3·0 +
C7 0·58 – 0·06 – 5·5 × 1011 > 3·0 +
C1 0·13 – 0·04 – 4·8 × 1011 > 3·0 +
C2 0·08 – 0·06 – 4·6 × 1011 > 3·0 +
C6 0·24 – 0·05 – 3·3 × 1011 > 3·0 +
C3 0·08 – 0·09 – 3·9 × 1011 > 3·0 +
PL9 0·11 – 0·06 – 1·4 × 1011 > 11·0 +
C5 2·02 + 0·17 – 7·2 × 108 1·0 +
E R 3·0 + 8·1 + 1·9 × 107 0·03 –
PL1 6·3 + 1·95 + 1·6 × 107 0·39 –
C8 0·15 – 2·56 + 2·6 × 104 0·04 –
D T 2·3 + 6·2 + 7·4 × 103 0·07 –
R S 6·6 + 6·8 + 8·9 × 103 0·42 –
PL20 0·11 – 4·78 + 550 0·42 –
PL16 0·2 – 4·80 + 200 0·39 –
Table 1 Parvovirus B19 detection by antigen 
enzyme immunoassay (EIA) and serological 
analysis (B19 IgM and IgG) of specimens 
previously quantified by polymerase chain 
reaction (PCR) (copies per ml). For the antigen EIA 
an index value (IV) ≥ 1·0 is positive (+) and < 1·0 is 
deemed negative (–). For both the B19 IgM and 
IgG EIA IV > 1·1 is positive; IV < 0·9 is negative; 
and IV between < 1·1 and IV > 0·9 is deemed 
equivocal (eq)
Fig. 3 Comparison of erythrovirus genotype 1 and 3 VP2 reactivity in the 
antigen enzyme immunoassay (EIA). Genotype 1 (clear and horizontal lined 
bars) and genotype 3 (diagonal lined and filled bars) recombinant VP2 was 
decimally diluted in either Tris-buffered saline Tween-20 (TBST) (clear and 
diagonal lined bars) or the proprietary low pH buffer (horizontal lined and 
filled bars). Error bars represent the standard deviation from the mean.
 
Table 2
 
Effect of B19 IgM and IgG in plasma on the detection of B19 
antigen. B19 antigen enzyme immunoassay (EIA) and serology results for 
plasma from patients with suspected B19 infection. For the antigen EIA an 
index value (IV) 
 
≥
 
 1·0 is positive (+) and < 1·0 is deemed negative (–). For both 
the B19 IgM and IgG EIA an IV > 1·1 is positive; IV < 0·9 is negative; and IV 
between < 1·1 and > 0·9 is deemed equivocal (
 
eq
 
)
 
Sample Identifier IgM EIA IV IgG EIA IV Antigen EIA IV
Cut-off calibrator 6·77 + 0·99 eq 1
931 0·14 – 0·70 – 18·6
420 0·16 – 0·90 eq 18·3
981 1·73 + 1·50 + 18·1
410 0·25 – 0·90 eq 18·1
375 0·14 – 0·70 – 18·1
939 0·30 – 0·80 – 18·0
889 4·99 + 1·70 + 17·9
976 0·17 – 1·20 + 17·8
441 3·40 + 0·80 – 17·6
973 0·28 – 1·28 + 17·3
966 1·92 + 1·46 + 17·3
936 1·21 + 1·40 + 16·3
444 0·86 – 1·00 eq 15·4
980 0·71 – 1·70 + 12·0
427 2·06 + 0·80 – 11·9
929 2·74 + 1·40 + 11·2
888 0·25 – 1·10 + 8·2
925 1·32 + 1·50 + 6·76
416 6·89 + 2·80 + 1·3
895 6·02 + 1·90 + 1·0
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(range: 3·1 × 106–3·2 × 1012 IU/ml; mean: 1·1 × 1012 IU/ml,
median: 1·2 × 1012 IU/ml B19 DNA) (Fig. 4). Thus, Fig. 4
depicts the combined B19 IgM and antigen EIA data of the
70 viraemic specimens, and the x-axis is arranged to show
the rise (106–1012 IU/ml) and subsequent drop in viraemia with
the development of B19-specific IgM antibodies (1012–106
IU/ml). Testing further revealed that the panel of viraemic
specimens was either pre- or early antibody seroconversion
as none contained B19 IgG (data not shown).
There was a positive correlation (correlation coefficient
r = 0·81) between the level of B19 DNA (qPCR) and the level
of B19 antigenemia (antigen EIA), but this relationship was
not directly proportional. Concordance between qPCR and
the antigen EIA was highest when viraemia titres were high
(> 1 × 1011 IU/ml). Of the viraemic donor specimens, 27 (38·6%)
tested positive (IV > 1·1) or borderline positive (two specimens
were equivocal: IV ≤ 1·1, IV ≥ 0·9) for B19 IgM (Fig. 4). The
specimens that were equivocal for IgM reactivity reacted
strongly in the antigen EIA (IV > 19). The overlap between
the two groups was considerable and 17% of the specimens
tested positive for both B19 IgM and antigen (Fig. 4). Signi-
ficantly, 91% of the viraemic donors were positive for either
B19 IgM or antigen. Thus, these data clearly demonstrate that
the combined implementation of a screening algorithm for B19
IgM and antigen readily facilitates the detection of specimens
containing greater than 106 IU/ml B19 DNA equivalents.
Discussion
Here we describe a B19 antigen EIA for the direct detection
of B19 antigen in human plasma. The detection limit of the
assay was 0·01 ng/ml of purified recombinant VP2 capsids
(which theoretically corresponds to 1·9 × 106 viral particles
per ml). Using dilutions of viraemic serum, the sensitivity was
estimated at between 4 × 107 and 108 copies per ml B19 DNA
equivalents. The antigen EIA was capable of detecting both
erythrovirus genotypes 2 (virus) and 3 (recombinant capsids).
When the antigen assay was used to test B19 viraemic donations,
70% tested positive of which had viral loads between
3·1 × 106 and 3·2 × 1012 IU/ml.
B19 detection in plasma was greatly enhanced by specimen
acidification. The low pH conditions may act by disrupting
the viral capsid into its structural subunits, making it more
accessible to the capture antibody. Although it was previously
thought that B19V was highly resistant to physicochemical
treatments, more recent work has shown the susceptibility of
B19V to low pH treatment [24]. Boschetti et al. [24] showed
that B19V was inactivated by greater than 5 logs after 2 h at
pH 4 and that infectivity also decreased.
When the antigen assay was performed at physiological
pH, the specimens that gave the highest absorbance values
were B19 IgM negative, implying immune complexes hinder
detection. However, when specimens were prepared in low
pH conditions, neither the presence of IgM nor IgG, even at
high levels, affected the detection of B19 (Table 2). It is probable
that acidification caused the dissociation of any immune
complexes present. False-negative results due to immuno-
complexes present a problem for B19 RHA assays, which
exploit the binding of a B19V receptor to red blood cells [11].
Hence, the RHA assay is ineffective for antigen detection in
specimens that have seroconverted a problem resolved by the
B19 antigen EIA.
B19 detection by PCR has a greater sensitivity, but such assays
have many disadvantages (e.g. potential cross-contamination)
not shared with an EIA. First, although erythrovirus genotypes
may diverge significantly at the genomic level [25,26],
requiring primer optimization [13], there does not appear to
be any antigenic or immunological differences between the
genotypes. The antigen EIA could identify genotype 2 eryth-
rovirus and genotype 3 recombinant VP2 capsids at the same
sensitivity as genotype 1. This is supported by the fact that all
three erythrovirus genotypes can haemagglutinate human red
blood cells and also infect myeloid cells with equal efficiency
[27]. Second, the significance of DNA in plasma postviraemia
Fig. 4 A summary of the B19 antigen enzyme immunoassay (EIA) and immunoglobulin M (IgM) EIA reactivity of the panel of viraemic donors. An index value 
(IV) > 1·1 (denoted by line) is considered positive on both the B19 IgM EIA (filled bars) and antigen EIA (clear bars). The y-axis was truncated for clarity.
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is unclear as low levels of B19 DNA can persist for several
years post-infection, even after IgM is lost and IgG reactivity
has been established [28]. A virus detection assay, however,
allows simultaneous testing of hundreds of specimens, is
suitable for large-scale screening, is more economical and
has a shorter time to result.
Combined B19 antigen and IgM EIA analysis of the viraemic
donor specimens revealed that 91% of the donor specimens
could be diagnosed as acute infection using this screening
algorithm. Previously, clinical samples taken from individuals
with a suspected B19 infection, which had a level of B19 DNA
greater than 105 IU/ml, were shown to be positive for specific
IgM also [20]. This was not the case with the Dutch donor
specimens herein, as this panel was from asymptomatic
individuals whose infection was detected due to routine
screening. Donor specimens, therefore, would be from all
stages post-infection including the preseroconversion stage.
Experimental infection has shown that B19 infection has two
phases [29], characterized by symptom-free initial high
viraemia (~1011 copies per ml serum) followed by detectable
IgM antibody and appearance of symptoms such as rash and
arthralgia. IgM seroconversion causes a rapid decline of viral
titre. The 70 viraemic specimens identified in this study
showed a typical viraemia and IgM seroconversion pattern
(Fig. 4), confirming that the donor samples are representative
of all stages of acute infection.
It is important to confirm the diagnosis of acute B19 infection
in a public health setting where an outbreak could lead to
serious medical consequences, especially for pregnant women
and immunocompromised patients. In addition, B19 screening
of blood donors prior to donation would avoid the risk of
contaminating blood products. The B19 antigen EIA in
conjunction with specific B19 IgM detection offers an effective
method of detecting acute infection.
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